Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Fair Value Measurements - Avenue's Contingently Issuable Warrants with option pricing model (Detail)

v3.6.0.2

Fair Value Measurements - Avenue's Contingently Issuable Warrants with option pricing model (Detail)	1 Months Ended	5 Months Ended	12 Months Ended
	Oct. 30, 2015	Aug. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Avenue [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			2.45%	2.27%
Expected dividend yield			0.00%	0.00%
Expected term in years			10 years	9 years 10 months 2 days
Expected volatility			87.00%	83.00%
Probability of issuance of the warrant			50.00%	25.00%
Mustang [Member] \| Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			1.37%
Expected dividend yield			0.00%
Expected term in years			10 years
Expected volatility			76.70%
Probability of issuance of the warrant			100.00%
Checkpoint [Member] \| Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.16%	2.26%
Expected dividend yield	0.00%	0.00%
Expected term in years	10 years	10 years
Expected volatility	100.86%	83.00%
Probability of issuance of the warrant	100.00%	25.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueAssumptionsExpectedDividendRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

+ Details

Name:	us-gaap_FairValueAssumptionsExpectedTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

+ Details

Name:	us-gaap_FairValueAssumptionsExpectedVolatilityRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

+ Details

Name:	us-gaap_FairValueAssumptionsRiskFreeInterestRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of likelihood a loan will not be repaid and instead default, used as an input to measure fair value.

+ References

+ Details

Name:	us-gaap_FairValueInputsProbabilityOfDefault
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fbio_AvenueTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fbio_MustangTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=fbio_ContingentlyIssuableWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fbio_CheckpointTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: